Insider Trading Alert - GNMK, CLRO And ADSK Traded By Insiders

Yesterday, June 7, 2016, 85 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $15.84 to $78,975,000.00.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 845 shares at $8.81 on June 7, 2016. Following this transaction, the SVP, Human Resources owned 195,051 shares meaning that the stake was reduced by 0.43% with the 845-share transaction.

Gleeson Michael, who is SVP, North American Com. Ops. at GenMark Diagnostics, sold 868 shares at $8.80 on June 7, 2016. Following this transaction, the SVP, North American Com. Ops. owned 254,834 shares meaning that the stake was reduced by 0.34% with the 868-share transaction.

Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 184 shares at $8.53 on June 7, 2016. Following this transaction, the SVP, International owned 139,229 shares meaning that the stake was reduced by 0.13% with the 184-share transaction.

Stier Eric, who is SVP & General Counsel at GenMark Diagnostics, sold 512 shares at $8.72 on June 7, 2016. Following this transaction, the SVP & General Counsel owned 111,048 shares meaning that the stake was reduced by 0.46% with the 512-share transaction.

The shares most recently traded at $9.20, up $0.48, or 5.17% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 582
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 3,363
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 38,638

The average volume for GenMark Diagnostics has been 195,900 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $386.8 million and is part of the health care sector and health services industry. Shares are up 16.75% year-to-date as of the close of trading on Tuesday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, commercializes, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology. Currently, there are 4 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings rates GenMark Diagnostics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full GenMark Diagnostics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ClearOne (CLRO) - FREE Research Report

Hendricks Larry, who is Director at ClearOne, sold 5,000 shares at $11.03 on June 7, 2016. Following this transaction, the Director owned 21,568 shares meaning that the stake was reduced by 18.82% with the 5,000-share transaction.

The shares most recently traded at $11.06, up $0.03, or 0.27% since the insider transaction. Historical insider transactions for ClearOne go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 11,718
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 11,718
  • 24-Week # shares sold: 20,000

The average volume for ClearOne has been 10,400 shares per day over the past 30 days. ClearOne has a market cap of $102.8 million and is part of the technology sector and telecommunications industry. Shares are down 11.83% year-to-date as of the close of trading on Tuesday.

ClearOne, Inc., together with its subsidiaries, designs, develops, and sells conferencing, collaboration, streaming, and digital signage solutions for audio/voice and visual communications in the United States and internationally. The stock currently has a dividend yield of 1.8%. The company has a P/E ratio of 15.4. Currently, there is 1 analyst who rates ClearOne a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLRO - FREE

TheStreet Quant Ratings rates ClearOne as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full ClearOne Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Autodesk (ADSK) - FREE Research Report

Bass Carl, who is Chief Executive Officer at Autodesk, sold 10,463 shares at $58.40 on June 7, 2016. Following this transaction, the Chief Executive Officer owned 195,240 shares meaning that the stake was reduced by 5.09% with the 10,463-share transaction.

The shares most recently traded at $58.50, up $0.10, or 0.17% since the insider transaction. Historical insider transactions for Autodesk go as follows:

  • 4-Week # shares sold: 5,300
  • 12-Week # shares sold: 82,438
  • 24-Week # shares sold: 137,438

The average volume for Autodesk has been 1.8 million shares per day over the past 30 days. Autodesk has a market cap of $13.2 billion and is part of the technology sector and computer software & services industry. Shares are down 3.67% year-to-date as of the close of trading on Tuesday.

Autodesk, Inc. operates as a design software and services company worldwide. Currently, there are 7 analysts who rate Autodesk a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADSK - FREE

TheStreet Quant Ratings rates Autodesk as a hold. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full Autodesk Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Tuesday Turnaround: Google Gets Grilled

Tuesday Turnaround: Google Gets Grilled

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Market Madness: This Market Is for Stock Pickers

Market Madness: This Market Is for Stock Pickers

Jim Cramer: The Operative Term for This Tape Is Treacherous

Jim Cramer: The Operative Term for This Tape Is Treacherous